Not much fun

While the toy makers are enjoying a pretty good run these days the same cannot be said for insulin companies. On a year to date basis shares of Lilly (NYSE: LLY) are up just under 2%, Sanofi (NYSE: SNY) down almost 10% and Novo Nordisk (NYSE: NVO) down almost 17%. Novo shares were hit hard at the end of last week when a report in Danish newspaper stated the company was going to lay off 3000 employees and will be withdrawing their long term financial guidance.

To pour salt in the wound the companies are also facing a . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.